An Exciting Development in Cell Therapy for Autoimmune Disorders! Century Therapeutics, Inc. secures Funding, and acquires Clade Therapeutics, to support the expansion of its autoimmune pipeline! Here are some of the highlights: 🚀The incorporation of three preclinical-stage programs from Clade's αβ iT platform, spanning cancer and autoimmune diseases (such as Myasthenia Gravis), will address critical unmet needs! 🔍 The CALiPSO-1 trial for SLE, (an innovative iPSC-derived iNK cell therapy) is poised for additional regulatory filings in 2024. 💰A $60 million private placement led by Bain Capital ensures Century Therapeutics, Inc.'s financial stability into 2026, fueling the development of autoimmune therapies 🗣️CEO, Brent Pfeiffenberger, states "Today's news signifies a transformative milestone for Century, as we accelerate and broaden our research and development initiatives in autoimmune diseases and iPSC-derived cell therapy on a larger scale" Stay tuned as Century Therapeutics, Inc develops its autoimmune disease treatments! #CenturyTherapeutics #Innovation #AutoimmuneDisease #celltherapy #CART #SLE #lupus #biotechnology
Thomas Vos’ Post
More Relevant Posts
-
BioInformant.com, World's Largest Publisher of Stem Cell News | Real Estate Investor | PatriotHoldings.com, Board Member, & Advisor | Former USA Rugby Player
More momentum in the area of iPSC-derived cellular therapeutics: "Century Therapeutics, Inc and FUJIFILM Cellular Dynamics to Commercialize iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases" Century Therapeutics, Inc. (NASDAQ: IPSC), an innovative clinical-stage biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immune-oncology, and FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human iPSCs and iPSC-derived cells, announce a new worldwide license agreement and expansion of existing licenses for the development and commercialization of cell therapies derived from iPSCs for the treatment of autoimmune and inflammatory diseases, including type 1 diabetes, multiple sclerosis, lupus, and rheumatoid arthritis. Read more at: https://lnkd.in/g2eJ8Fhz #ipscells #stemcells #cellthearpy #immunotherapeutics
Century Therapeutics and FUJIFILM Cellular Dynamics to Commercialize iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases
https://bioinformant.com
-
𝗡𝗞 𝗰𝗲𝗹𝗹 𝘁𝗵𝗲𝗿𝗮𝗽𝗶𝗲𝘀: 𝗮 𝗴𝗮𝗺𝗲 𝗰𝗵𝗮𝗻𝗴𝗲𝗿 𝗳𝗼𝗿 𝗰𝗮𝗻𝗰𝗲𝗿 𝗮𝗻𝗱 𝗮𝘂𝘁𝗼𝗶𝗺𝗺𝘂𝗻𝗲 𝗱𝗶𝘀𝗲𝗮𝘀𝗲 𝘁𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁𝘀? Natural killer cells (NK cells) are white blood cells that destroy infected and diseased cells like cancer cells. NK cells are being used in clinical applications to treat a range of diseases. Clinical trials of NK cell infusion have shown promising results, and chimeric antigen receptor (CAR) NK cell therapies have also been making their way to the clinic. More and more biotechs are raising funding to advance their NK cell therapy candidates in the clinic. Take a look! #immunotherapy #immunity #NK #cancer #autoimmunity #innovation #biotech #medicine
Exciting times in life sciences recruitment! The evolving landscape of NK cell therapies is a game-changer for cancer and autoimmune disease treatments. With the FDA greenlighting new therapies and clinical trials showing promising results, companies like Artiva Biotherapeutics, Dragonfly Therapeutics, Inc., and Fate Therapeutics Inc are leading the charge. Their innovative approaches, like Artiva's AlloNK and Dragonfly's TriNKETs, are also tackling autoimmune diseases like lupus nephritis. This progress signals a surge in demand for specialised talent in biotech. As a recruitment company, we're poised to bridge this gap, connecting groundbreaking biotechs with the brightest minds in the field. Whether it's in R&D, clinical trials, or biotech marketing, the opportunities for professionals in this space are vast and growing. We're here to help you navigate this exciting frontier! https://lnkd.in/dSTFKgVt #AspireLifeSciences #Recruitment #BiotechInnovation #NKTCellTherapy #CareerOpportunities
Ten NK cell therapy companies to look out for this year
https://www.labiotech.eu
-
Cartesian Therapeutics, an mRNA cell therapy biotech, announced its BCMA-directed CAR-T therapy Descartes-08 met the primary endpoint in a Phase 2b study for the nerve communication-destroying disease myasthenia gravis (MG). The biotech switched its primary endpoint from the MG-ADL symptom scale to MGC. Descartes-08 helped 71% of patients achieve 5-point or greater improvement on a 60-point scale of the disease. That compared to 25% of patients who received placebo, with a p-value of 0.018. Cartesian did share results from a per-protocol population that included 31 patients. In that population, the MGC response rates in the Descartes-08 and placebo arms were 69% and 33%, respectively, resulting in a p-value of 0.048
Cartesian claims phase 2b autoimmune CAR-T win after changing endpoint
fiercebiotech.com
-
Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe
The potential utilization of CAR-T therapy for combating lupus could truly be groundbreaking, with Kyverna Therapeutics leading the charge. This innovative approach involves the transformation of a patient's immune cells to precisely target and neutralize the cells responsible for triggering the autoimmune response. Whilst the use of CAR-T therapy has primarily been associated with cancer treatment, its application in autoimmune disease represents the tip of the iceberg in terms of the potential for cell therapy in this area. The promising results of early clinical trials suggest that CAR-T therapy could potentially offer a new avenue for addressing the underlying causes of lupus and other autoimmune conditions 💉🔬 Hypothetically, the expansion of CAR-T therapy to treat autoimmune diseases presents an exciting opportunity for professionals in the biotech and pharmaceutical industry. This development not only highlights the ongoing innovation within the field of immunotherapy, but also underscores the importance of interdisciplinary collaboration to address complex medical challenges 🤝💊 #KyvernaTherapeutics #AutoimmuneDisease #CellTherapy #CAR-T #MedicalInnovation #Biotechnology #Pharmaceuticals #ClinicalResearch #ClinicalTrials #LifeScience #ElixirAssociates #StaffingPartner
CAR-T for lupus: the ‘tip of the iceberg’ for cell therapy in autoimmune disease 💊
biopharmadive.com
-
Access pioneering organoid panel screens for translatable results. Fast-track your oncology drug development with results from 50 models in just 6 weeks. Identify lead compounds, stratify patient responses, and preselect models for in vitro and in vivo studies. Rigorous Validation: Benefit from 50 well-characterized PDO and PDXO models for enhanced precision. Explore diverse genetic backgrounds and clinically relevant mutational profiles, including KRAS, BRAF, BRCA 1 and 2, and EGFR. Embrace Reliability: Our organoids undergo rigorous validation and quality assurance, including SNP verification and mycoplasma testing. Quantify cell viability and explore potential drug combinations, all well-characterized against standard-of-care agents. Dive into Diversity: Leverage unparalleled model diversity, choose the panel that best suits your research needs, and ensure accuracy and reproducibility with a semi-automated workflow. 🚀 Don't miss this exciting journey into the future of oncology research with Organoids. Crown Bioscience leads the way! #CrownBioscience #InnovationInOncology #ScientificAdvancements #OrganoidXplore #CancerResearch #PrecisionScience #InnovationInOncology #OrganoidAdvancements #CrownBioscience #PrecisionMedicine #OncologyBreakthroughs #PreclinicalResearch #ScientificExcellence #DiseaseModeling #TranslationalMedicine #PrecisionDrugDiscovery Crown Bioscience Crown Bioscience & MBL https://lnkd.in/eJtwHAmj
Crown Bioscience Introduces OrganoidXplore: Revolutionizing Cancer Research with Rapid Large-scale Organoid Drug Screening
crownbio.com
-
Leukemia Therapeutics Market Size, Share & Trends Analysis Report By Disease Condition (Acute lymphocytic leukemia, Chronic lymphocytic leukemia, Acute myeloid leukemia, Chronic myeloid leukemia) By Treatment (Immunotherapy, Targeted Therapy, Bone Marrow Transplant, Stem Cell Therapy), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 🌐𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐯𝐭. 𝐋𝐭𝐝. 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/d5ckymb8 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭: AbbVie., Affimed Allergan, Amgen AstraZeneca, Biogen, Boehringer Ingelheim Bristol-Myers Squibb Pharma Company, Cardiff Oncology Celgene Clovis Oncology, Curis Evexta Bio Eisai US PHAXIAM Therapeutics Exelixis, F. Hoffmann-La Roche Ltd Genzyme Genetics, Gilead Sciences., GSK Golden Biotechnology Corp (4132) 國鼎生技 Immune-Onc Therapeutics Johnson & Johnson Kronos Bio LAVA Therapeutics N.V. Lupin MaaT Pharma MediSix Therapeutics Merck Group. MorphoSys Novartis ONO PHARMACEUTICAL CO., LTD., Oryzon Genomics SA Pfizer Prescient Therapeutics Ryvu Therapeutics Sanofi Starton Therapeutics Sunesis Pharmaceuticals, Inc. #leukemia #cancer #cancersucks #childhoodcancer #cancerawareness #breastcancer #bloodcancer #childhoodcancerawareness #cancersurvivor #leukemiaawareness #lymphoma #pediatriccancer #health #cancersupport #cervicalcancer #leukemiawarrior #chemotherapy #fuckcancer #pancreaticcancer #cancerwarrior #gogold #morethan #diabetes #cancerfighter #skincancer #kidsgetcancertoo #beatcancer #aml #thyroidcancer #hope
-
-
BridGene Biosciences, Inc. is revolutionizing the drug discovery landscape with their innovative approach to targeting hard-to-drug proteins. Their chemoproteomics platform enables them to identify and validate novel drug targets with unprecedented precision. Partnering with leading pharmaceutical companies, they're accelerating drug discovery and development processes across various therapeutic areas, including oncology, immunology, and neurology. With a visionary executive team, BridGene brings a wealth of experience to overcome some of the toughest challenges in modern medicine. Learn more about their mission and methodologies in this groundbreaking interview. #DrugDiscovery #Biotechnology #Pharmaceuticals #Innovation #Chemoproteomics #Oncology #Immunology #Neurology #BridGeneBiosciences #HealthcareInnovation David Schemelia Ping C.
BridGene Biosciences and How It Aims to Target Hard to Drug Proteins
https://www.clinicaltrialvanguard.com
-
The CAR T-Cell Therapy Market is swiftly evolving, witnessing remarkable advancements in personalized cancer treatment. With ongoing research and clinical trials, innovative therapies are emerging, offering hope for patients with hematologic malignancies and solid tumors. This dynamic landscape underscores the transformative potential of immunotherapy in reshaping cancer care. Some of the leading companies in the CAR T-Cell Therapy Market include CytoAgents, Inc., Genentech., Incyte, Caribou Biosciences, Chimeric Therapeutics, Allogene Therapeutics, Kyverna Therapeutics, iCell Gene Therapeutics, Synthekine, Janssen Inc., ImmPACT Bio, A2 Biotherapeutics, Inc., Gracell Biotechnologies, Oncternal Therapeutics, CARsgen Therapeutics, Autolus Therapeutics, Arcellx, Kite Pharma, Novartis, Lyell Immunopharma, ImmPACT Bio, Tmunity Therapeutics Incorporated, Poseida Therapeutics, Inc., Precigen, AffyImmune Therapeutics, 2seventy bio, Takeda, Cartesian Therapeutics, Cabaletta Bio, Legend Biotech, Miltenyi Biomedicine, Beam Therapeutics, and others. Get a more detailed overview at: https://lnkd.in/gq2JvRTQ #CARTcell #immunotherapy #cancerresearch #personalizedmedicine #celltherapy #medicalinnovation #cancerimmunotherapy #oncology #tcelltherapy #hematologicalmalignancies
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032)
prnewswire.com
-
Lymphoma Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Hodgkin By, Non-Hodgkin By) By Treatment Drug (Adcetris, Opdivo, Rituxan/MabThera, Imbruvica, Keytruda, Revlimid, Others), Global Economy Insights, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast, 2023 - 2031. 🌐𝐈𝐌𝐈𝐑 𝐌𝐚𝐫𝐤𝐞𝐭 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐏𝐯𝐭. 𝐋𝐭𝐝. 𝐆𝐞𝐭 𝐭𝐡𝐞 𝐬𝐚𝐦𝐩𝐥𝐞 𝐫𝐞𝐩𝐨𝐫𝐭: https://lnkd.in/dFFn3pre 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬 𝐰𝐨𝐫𝐤𝐢𝐧𝐠 𝐢𝐧 𝐭𝐡𝐞 𝐦𝐚𝐫𝐤𝐞𝐭: 4SC AG Abbott Abintus Bio, Inc. Aldeyra Therapeutics Amgen Aptose Biosciences, Inc. Artiva Biotherapeutics AstraZeneca Atara Biotherapeutics Australasian Leukaemia & Lymphoma Group (ALLG) Bayer Bristol Myers Squibb Colorado Blood Cancer Institute Medical Group Curis Eli Lilly and Company Eureka Therapeutics, Inc Gilead Sciences GSK Halo House Foundation HematoLogics Inc. . Here to Serve, Inc. Hunterdon Hematology Oncology IASO BioTherapeutics（驯鹿生物） IGM Biosciences, Inc. ImpriMed, Inc. Imvax, Inc. Johnson & Johnson Karyopharm Therapeutics Inc. Life Line Stem Cell Lymphoma Action Merck Group Micromet AG Moleculin Biotech, Inc. Novartis PETHEMA Pfizer Queensland Veterinary Specialists Seagen #lymphoma #cancer #leukemia #bloodcancer #cancersucks #chemotherapy #hodgkinslymphoma #lymphomaawareness #cancersurvivor #cancerawareness #chemo #breastcancer #fuckcancer #cancerfighter #nonhodgkinslymphoma #myeloma #cancerwarrior #oncology #bloodcancerawareness #cancerresearch #lungcancer #lymphomasurvivor #stemcelltransplant #bonemarrowtransplant #childhoodcancer #prostatecancer #ovariancancer #multiplemyeloma #pancreaticcancer #beatcancer
-
